Immunotherapy with radiation for early-stage lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with stereotactic body radiation therapy (SBRT) for people with early-stage non-small cell lung cancer. The goal is to see if this treatment can help shrink or control the cancer before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that is stage IA to IIB (tumor up to 7 cm, with no spread to lymph nodes).
- You cannot have had any chemotherapy or radiation for this lung cancer before.
- Your cancer should not have a known genetic change (like EGFR, ALK, or ROS1) that is treated with a targeted pill.
- You must have a good general health status (able to do daily activities without help).
- You cannot have active serious lung disease (like tuberculosis, pneumonitis, or interstitial lung disease) or an active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests combining immunotherapy with chemotherapy for people with stage III non-small cell lung cancer that cannot be removed by surgery. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial studies whether adding toripalimab (an immunotherapy medicine) to radiation can improve outcomes for people with operable stage II to IIIA non-small cell lung cancer. It’s designed for cancers that can be fully removed with surgery, and it aims to see if this combination helps more than radiation alone/standard care.
This trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) combined with chemotherapy given before surgery to remove stage III lung cancer. The goal is to shrink the tumor and improve survival chances by boosting your immune system to fight the cancer.
This trial is testing a combination of immunotherapy and targeted radiation for people with advanced lung cancer that has no targetable gene changes. The goal is to see if adjusting radiation based on how well the tumor responds can improve outcomes.
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.